Genetic Technologies Reports Q1 FY22 Results
Retrieved on:
Monday, October 25, 2021
Woman, Genetypes, Colorectal cancer, Polygene, IBX, Ovarian cancer, Epidemiology, Marketing, National, ASX, COVID-19, Colditz, NATA, Health, Acquisition, GLOBE, Research, DTC, National public health institutes, Completeness, Company, Direct, Norwegian Institute of Public Health, Institute, Coronary artery disease, European, IBX Group, Risk, Public health, Genetic causes of type 2 diabetes, Awareness, PLOS, Biobank, Population, GTG, Breast cancer, Single-nucleotide polymorphism, Cancer, Certification, NASDAQ, CIT, Applied Genetic Technologies Corporation, Board, Washington University in St. Louis, Roy Taylor (scientist), Type 2 diabetes, Prostate cancer, UK Biobank, Agriculture, Pharmaceutical industry, Fine chemical, Video game, Medical device, Birth control
The Multi-Test is a Predictive Panel Risk Test to cover six common cancers which account for ~70% of annual morbidities.
Key Points:
- The Multi-Test is a Predictive Panel Risk Test to cover six common cancers which account for ~70% of annual morbidities.
- Phase one launch to include Breast Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Coronary Artery Disease and Type-2 Diabetes.
- Commenting on the quarter, CEO Simon Morriss stated: This past quarter demonstrates the forward trajectory and momentum Genetic Technologies has established.
- Authorised for release by the Board of Genetic Technologies Limited.